Loading...
XWARBIO
Market cap58mUSD
Dec 23, Last price  
2.81PLN
1D
-3.77%
1Q
-16.37%
Jan 2017
-65.61%
IPO
-92.27%
Name

Bioton SA

Chart & Performance

D1W1MN
XWAR:BIO chart
P/E
106.06
P/S
1.33
EPS
0.03
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-5.51%
Revenues
182m
-22.10%
151,586,000215,479,000270,942,000293,517,000286,228,000378,595,000288,984,000406,303,000340,358,000377,303,000404,408,000277,613,000361,649,000241,166,000202,032,000221,788,000163,034,000233,159,000181,636,000
Net income
2m
+60.10%
34,627,00092,698,00026,572,000-223,033,000-599,878,000110,726,000-83,936,00037,837,000-6,443,0003,678,000-522,855,000-28,567,000-7,266,00026,266,000-126,693,00033,920,0002,882,0001,421,0002,275,000
CFO
40m
-29.34%
7,127,000-10,763,000-530,00037,745,000-80,222,00027,170,000-22,200,000144,796,00079,963,00041,874,00024,023,00023,146,00017,503,00027,880,00046,707,00041,949,0005,522,00056,082,00039,625,000

Profile

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
URL
https://bioton.com/
IPO date
Mar 16, 2005
Employees
355
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
181,636
-22.10%
233,159
43.01%
163,034
-26.49%
Cost of revenue
185,745
208,086
149,605
Unusual Expense (Income)
NOPBT
(4,109)
25,073
13,429
NOPBT Margin
10.75%
8.24%
Operating Taxes
4,959
3,531
5,449
Tax Rate
14.08%
40.58%
NOPAT
(9,068)
21,542
7,980
Net income
2,275
60.10%
1,421
-50.69%
2,882
-91.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
56,016
57,737
80,618
Long-term debt
26,816
32,925
44,857
Deferred revenue
29,814
32,745
36,257
Other long-term liabilities
3,421
(20,686)
10,341
Net debt
78,949
79,966
114,475
Cash flow
Cash from operating activities
39,625
56,082
5,522
CAPEX
(44,166)
(29,578)
(12,892)
Cash from investing activities
(36,952)
(29,100)
(4,284)
Cash from financing activities
(8,129)
(26,499)
(14,621)
FCF
(13,471)
56,013
(20,345)
Balance
Cash
3,883
9,339
8,857
Long term investments
1,357
2,143
Excess cash
2,848
Stockholders' equity
549,227
635,404
652,208
Invested Capital
708,286
691,302
770,820
ROIC
2.95%
1.04%
ROCE
3.46%
1.73%
EV
Common stock shares outstanding
85,864
85,864
85,864
Price
3.57
5.93%
3.37
-19.47%
4.19
-3.35%
Market cap
306,535
5.93%
289,362
-19.47%
359,342
-3.35%
EV
385,484
455,803
560,417
EBITDA
30,875
59,476
45,067
EV/EBITDA
12.49
7.66
12.44
Interest
8,427
7,858
4,539
Interest/NOPBT
31.34%
33.80%